• facebook
  • twitter
  • linked in
  • google+
back top

Scientific Agenda

Scientific Agenda

Biologics Alliance Summit & Think Tank

5 February (Wednesday)

  • 12:30 - 18:15
    Biologics Alliance Think Tank (upon invitation only)
    The Think Tank format will be similar to the television show: “Shark Tank".  Presenters (“contestants”) will be industry or academic researchers with new orthobiologic ideas, products, applications, etc. They will appear before a panel of judges similar to those on Shark Tank, only these judges have special expertise in orthopedics/OrthoBiologics. After the judging panel has completed their questions and suggestions, the presenters will take question from a panel of industry reporters/analysts and then from the floor. The session will end with recommendations from the Judges who will also score the presenters to allow for a “winner” at the conclusion of the day. Judges/Sharks: Scott Bruder, Laurence Higgins, Nicholas Pachuda, Christopher Shen Reporters/Analysts: Kim French, Sharon O'Reilly, Robin Young, Patrick Duffey
  • 12:30 - 14:00
    Session 1
    • 12:30 - 13:00
    • 13:00 - 13:30
    • 13:30 - 14:00
  • 14:00 - 14:30
  • 14:30 - 16:00
    Session 2
    • 14:30 - 15:00
    • 15:00 - 15:30
      Orthopedic Stem Cell Research Lab, Regenerative Medicine Institute, Cedars-Sinai
      We aim to identify cell and protein biomarkers in platelet-rich plasma (PRP) that correlate with reduced knee osteoarthritis (OA)-associated pain levels post-PRP treatment to allow for prediction of PRP therapy efficacy. This study will provide a thorough analysis of PRP cell and protein biomarker composition and its effect on clinical outcomes and thus will allow to identify the main contributors to PRP’s efficacy. These findings will allow to define new standards of PRP composition, leading to higher success rates in PRP therapy for knee OA.
    • 15:30 - 16:00
      Regenacell Therapy
      Marrow Cellution device and the CellFUSE - Bone Graft Substitute
  • 16:00 - 16:30
  • 16:30 - 18:00
    Session 3
    • 16:30 - 17:00
      Keck School of Medicine of USC: Evaluation of Engraftable Human Pluripotent Stem Cell-Derived Chondrocytes in a Long-Term Preclinical Pig Model of Focal Cartilage Injury
      Our group of scientists and clinicians has been continuously funded by the California Institute of Regenerative Medicine (CIRM) to develop a first-in class pluripotent stem cell-based therapy for focal articular cartilage lesions. Plurocart® is an off-the-shelf allogeneic cryopreserved bioreactor-made biological implant composed of highly purified human stem cell-derived immature articular chondrocytes. Detailed molecular, cellular and functional characteristics of the Plurocart® technology will be presented.
    • 17:00 - 17:30
      Bioventus: Preclinical Characterization and Clinical Development Plans for PTP-001, a Novel Human Tissue Biologic in Development For The Treatment of Osteoarthritis.
      To date, all attempts to develop disease-modifying therapies for OA have failed, principally due to lack of clinical efficacy or safety issues. Such treatments have generally focused on modulation of a single target (e.g. a specific cytokine or enzyme/protease) whereas OA is a complex, mutifactorial disease process. PTP-001 is an effective tissue-derived treatment, with an inherent multi-modal MOA that can impact a number of pathologic pathways (including pain and tissue damage) which contribute to OA. This presentation will focus on the evidence and the development plans for PTP-001 as a regulated biologic product, in concordance with FDA guidance, as a novel approach for the treatment of OA and other musculoskeletal conditions.
    • 17:30 - 18:00
  • 19:00 - 21:00
    Ice Breaker - Welcome Cocktail

6 February (Thursday)

7 February (Friday)